Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Junta Nakajima
Observed name:
J. Nakajima
Institution:
Obihiro Kosei General Hospital
Observed institutions:
Hokkaido University,
Obihiro Kosei General Hospital,
Institute for Genetic Medicine, Hokkaido University
OpenAlex ID:
A5011892798
Open‐label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron
2015
·
Yoshito Komatsu
, Kenji Okita
, et al.
·
Cancer Science
·
52
PDF
A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II)
2018
·
Kazuhiro Nishikawa
, Akira Tsuburaya
, et al.
·
European Journal of Cancer
·
19
Paired-like homeoprotein ESXR1 acts as a sequence-specific transcriptional repressor of the human K-ras gene
2005
·
Masatomo Yanagihara
, Susumu Ishikawa
, et al.
·
Oncogene
·
12
[Clinical efficacy of adalimumab for a postoperative marginal ulcer in gastrointestinal Behçet disease].
2012
·
Yui Shimizu
, Tsuyoshi Takeda
, et al.
·
PubMed
·
9
A randomized phase II trial of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment versus SP randomized PII trial (XParTS II).
2015
·
Michiya Kobayashi
, Akira Tsuburaya
, et al.
·
Journal of Clinical Oncology
·
6
Current Status of Hepatocellular Carcinoma Treatment in Japan: Practical Use of Sorafenib (Nexavar®)
2012
·
Norihiro Kokudo
, Junta Nakajima
, et al.
·
Clinical Drug Investigation
·
4
Anti-tumor activity of ESX1 on cancer cells harboring oncogenic K-ras mutation
2008
·
Junta Nakajima
, Susumu Ishikawa
, et al.
·
Biochemical and Biophysical Research Communications
·
4
A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer [HGCSG1503]: Updated analysis
2017
·
S. Yuki
, Y. Komatsu
, et al.
·
Annals of Oncology
·
1
PDF
HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index
2018
·
K. Suzuki
, S. Yuki
, et al.
·
Annals of Oncology
HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index
2018
·
K. Hatanaka
, S. Yuki
, et al.
·
Annals of Oncology
A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer (HGCSG1503): Analysis of cases of prior regorafenib.
2018
·
Atsushi Ishiguro
, Satoshi Yuki
, et al.
·
Journal of Clinical Oncology
First report: A retrospective trial for evaluating the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer: HGCSG1503
2017
·
H. Yoshita
, S. Yuki
, et al.
·
Annals of Oncology
PDF
First report: A retrospective trial for evaluating the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer: HGCSG1503
2017
·
Masayoshi Dazai
, Satoshi Yuki
, et al.
·
Annals of Oncology
Existence of a subgroup with good prognosis in non-small cell lung cancer with intrapulmonary metastases
1994
·
J. Nakajima
, T. Kono
, et al.
·
Lung Cancer
Show more works
View as search
Works count:
14
Citation count:
107
H-index:
5
I10-index:
3
Year
Topic
Type